Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics1 passage
• Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF1 passage
• Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial1 passage
• Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial data1 passage
• Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial1 passage
• Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial1 passage
• Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trial1 passage
• Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial1 passage
• Burst steroid therapy for acute heart failure: The CORTAHF randomized, open-label, pilot trial1 passage
• Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure1 passage
• Combination diuretic therapy in acute heart failure: A systematic review and meta-analysis1 passage
• Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta-analysis1 passage
• Diuretic resistance and the efficacy of hydrochlorothiazide in acute decompensated heart failure: A post-hoc analysis of the CLOROTIC trial1 passage
• Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved1 passage
• Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction1 passage
• Effect of influenza vaccination in patients with decompensated heart failure: a systematic review and meta-analysis1 passage
• Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure1 passage
• Effects of empagliflozin on uric acid levels during acute heart failure recompensation: A sub-analysis of the EMPAG-HF trial (Effects of Empagliflozin on Diuresis and Renal Function in Patients with Acute Decompensated Heart Failure)1 passage
• Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme1 passage
• Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: A systematic review and meta-analysis1 passage
• Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis1 passage
• Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial1 passage
• Finerenone, eplerenone, and spironolactone in heart failure with preserved ejection fraction: a Bayesian network meta-analysis of efficacy and safety1 passage
• Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved and mildly reduced ejection fraction - a meta-analysis of randomized controlled trials1 passage
• Health-related quality of life outcomes in PARAGON-HF1 passage
• Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)1 passage
• Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial1 passage
• Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX-AHF-2 trial1 passage
• Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study1 passage
• Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis1 passage
• Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial1 passage
• Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis1 passage
• Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE1 passage
• Nurse-led diuretic titration via a point-of-care urinary sodium sensor in patients with acute decompensated heart failure (EASY-HF): A single-centre, randomized, open-label study1 passage
• Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT1 passage
• Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: A prespecified sub-analysis of the PUSH-AHF study1 passage
• Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT1 passage
• Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure1 passage
• Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis1 passage
• Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction1 passage
• Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)1 passage
• Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies1 passage
• Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study1 passage
• Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial1 passage
• Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial1 passage
• Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis1 passage
• Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review1 passage
• Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial1 passage
• Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: A sub-analysis of the STRONG-HF randomized clinical trial1 passage
• Sex-specific analysis of the rapid up-titration of guideline-directed medical therapies after a hospitalization for acute heart failure: Insights from the STRONG-HF trial1 passage
• Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis1 passage
• Sodium and potassium changes during decongestion with acetazolamide - A pre-specified analysis from the ADVOR trial1 passage
• Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study1 passage
• Spironolactone, early acute eGFR changes, and clinical outcomes in patients with heart failure with preserved ejection fraction: insights from TOPCAT Americas1 passage
• Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF1 passage
• Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial1 passage
• The frailty syndrome and outcomes in the TOPCAT trial1 passage
• Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE1 passage